Atley develops novel technology for the production of At-211 labeled radiopharmaceuticals. The technology can have an important impact on the possibility to deliver new, efficient, and less toxic treatments for disseminated cancer.
The work requires a skilled and cross-functional team, as the technology must adhere to strict regulatory and user requirements:
- The technology must be able to produce radiopharmaceuticals following GMP
- The production needs to be fast and fully automated due to the short half life of At-211
- The technology needs to be safe and ergonomic for the operator